相关实验视频

Updated: May 15, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

2024年对EGFR抑制剂的年度审查

Chao Gao¹, Wanning Wang¹, Tong Liu¹

¹Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China; Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.

European journal of medicinal chemistry

|May 6, 2025

概括

2024年,新的表皮生长因子受体 (EGFR) 抑制剂被开发用于EGFR突变驱动的癌症,如非小细胞肺癌. 研究重点是药物设计,耐药性和组合疗法,以改善治疗策略.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

表皮生长因子受体 (EGFR) 抑制剂对于治疗具有特定EGFR突变的癌症至关重要,包括非小细胞肺癌 (NSCLC).
该领域在2024年取得了重大进展,涉及新药发现,理解耐药性途径和开发组合治疗方法.

研究的目的:

审查2024年发表的关于EGFR抑制剂的关键研究.
专注于设计策略,结构-活动关系 (SAR),作用机制和临床前 (体外和体外) 活动.
为开发更有效和更有选择性的EGFR抑制剂对抗多种突变提供新的视角.

主要方法:

在2024年发表的关于EGFR抑制剂的研究的文献综述.
药物设计,SAR,作用机制和实验数据 (体外和体内) 的分析.
综合发现以确定趋势和未来的研究方向.

主要成果:

识别具有提高疗效和选择性的新型EGFR抑制剂候选者.
阐明新出现的抵抗机制和克服它们的潜在策略.
对涉及EGFR抑制剂的有前途的组合疗法方案的评估.

结论:

2024年的研究环境为下一代EGFR抑制剂提供了有前途的途径.
了解SAR和耐药性是克服EGFR驱动癌症治疗挑战的关键.
需要进一步开发以将这些发现转化为不同EGFR突变的临床实践.

关键词:

设计策略设计策略作为EGFR抑制剂的使用.在NSCLCLC中,我们可以看到.阻力机制阻力机制

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...